KLK3 and posterior cortical atrophy: In this phase III study, 1006 patients with mCRPC were randomized to receive prednisone either in combination with mitoxantrone (a chemotherapy that provides palliation, but does not lead to an improvement in survival for patients with castration-refractory PCa (Tannock et al. 1996) or with docetaxel (a chemotherapy that has been reported in phase II studies to successfully reduce serum prostate-specific antigen (PSA) levels Beer et al. 2001, Berry et al. 2001).